Menu
Brokers
MT4 Forex Brokers
MT5 Forex brokers
PayPal Brokers
Skrill Brokers
Oil Trading Brokers
Gold Trading Brokers
Web Browser Platform
Brokers with CFD Trading
ECN Brokers
Bitcoin FX Brokers
PAMM Forex Brokers
With Cent Accounts
With High Leverage
Cryptocurrency Brokers
Forums
All threads
New threads
New posts
Trending
Search forums
What's new
New threads
New posts
Latest activity
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Reply to thread
Forums
Forex Discussions
Technical Analysis
Pfizer Inc. Technical Analysis
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
[QUOTE="IFC Markets, post: 211606, member: 18359"] [HEADING=1]Pfizer Inc. Technical Analysis[/HEADING] The technical analysis of the [B] Pfizer stock price [/B] chart on 4-hour timeframe shows #S-PFE,H4 is retracing up toward the 100-period moving average MA(100) which is rising itself. We believe the bullish momentum will continue after the price breaches above the last fractal high at 50.08. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed at 48.92. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (48.92) without reaching the order (50.08), we recommend cancelling the order: the market has undergone internal changes which were not taken into account. [HEADING=1]Fundamental Analysis of Stocks - Pfizer Inc.[/HEADING] Pfizer is buying Global Blood Therapeutics, a hemology drug maker. Will the [URL='https://www.ifcmarkets.com/en/market-data/stocks-prices/pfe'] Pfizer stock price[/URL] rebound continue? Pfizer signed a deal to pay $5.4 billion for Global Blood Therapeutics, a hemology drug maker which makes Oxybryta tablets for treating sickle cell disease. Pfizer Inc.'s revenue exceeded $16 billion in the second quarter. Couple of days ago FDA approved Myovant Sciences Ltd and Pfizer Inc's once-a-daily Myfembree for moderate to severe pain associated with endometriosis in pre-menopausal women. And yesterday an EU regulator began a review of Pfizer-BioNTech's variant-adapted COVID shot. Expectations of rising sales are bullish for company’s stock price. [ATTACH type="full"]22294[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Top
Bottom
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…